Trump's Ultimatum to Europe: Raise Drug Prices or Lose Access to New Medicines

The Trump administration is launching a broad diplomatic push across Europe, urging governments to raise drug prices to align with U.S. levels. U.S. embassies are actively lobbying European capitals, arguing that American patients bear excessive costs, paying up to three times more than in Germany for new medications. The U.S. wants Europe to shoulder a greater financial burden for pharmaceutical innovation.

“

If European countries do not yield, they risk losing major investments from pharmaceutical companies and delaying access to the latest medicines.

Sources familiar with the negotiations warn that European countries could face significant consequences if they refuse to yield. These include losing major investments from pharmaceutical companies and experiencing delays in accessing the latest medical treatments. The agreement reached with the United Kingdom, which granted British pharmaceutical firms three years of protection from U.S. tariffs in exchange for gradually increasing drug spending over a decade, has become a key model for this strategy.

Germany, Europe's largest drug market, is reportedly the next major target. Washington is pushing for increased spending, despite Germany's ongoing health system reforms aimed at reducing public expenditure on medicines. Confidential talks have been underway for months between German Health Minister Nina Warken, Economy Minister Katherina Reiche, and the U.S. Department of Health and Human Services, discussing billions in investments, trade policy, and drug pricing.

“

We are a little jealous of the agreement between the United Kingdom and the USA.

Industry insiders acknowledge the appeal of the U.S.-U.K. deal. The German pharmaceutical industry is already struggling with the market launch of new drugs. The Trump administration is exploiting the fragmented nature of European healthcare systems, where drug pricing is largely a national matter. To facilitate these negotiations, the U.S. Embassy in Berlin is sending its trade advisor to London to learn from British counterparts about implementing similar agreements. Meanwhile, pharmaceutical giants like Eli Lilly and Boehringer Ingelheim have already announced reductions in planned investments in Germany, citing the country's austerity measures. Similar investment freezes occurred in the UK before a deal was reached with the U.S.

“

The perpetrators often become very skilled at concealing their actions. It is not uncommon for fraud to go on for years and years. Eventually, they catch up with you.